Font size
S
M
L
XL
WorksheetsNeb Arise Knowledge Hour April 2023
Total questions: 30
Worksheet time: 23mins
Name
Class
Date
1.
________ % improvement in PEFR using _______, is used to confirm asthma in the ________.
a)
≥18%, peak flow meter, bronchodilator reversibility test
b)
≥12%, peak flow meter, bronchodilator reversibility test
c)
≥20%, peak flow meter, bronchodilator reversibility test
d)
≥30%, peak flow meter, bronchodilator reversibility test
2.
Management of acute asthma, mild or moderate condition
a)
SABA (4 to 10 puffs) + prednisolone + controlled oxygen
b)
SABA + Ipratropium Nebulize + O2
c)
SABA + Ipratropium Nebulize + O2+ systemic CS
d)
Inhaled SABA + systemic CS + Ipratropium + Magnesium Sulphate
3.
The preferred controller & reliver treatment in step 1& 2 asthma management strategy according to GINA 2021 is ______________
a)
As needed low dose ICS/Formoterol
b)
ICS monotherapy
c)
Medium dose ICS/Formoterol
d)
Formoterol
4.
As per GOLD guideline, ICS should be given as initial therapy in which category?
a)
Grade A
b)
Grade B
c)
Grade D
d)
Grade E
e)
none of above
5.
If a patient has CAT score 20 and he has 1 exacerbation not leading to hospitalization in last 13 months, then according to the GOLD 2019:
a)
He fits in GOLD Group A
b)
He fits in GOLD Group B
c)
He fits in GOLD Group D
d)
None
6.
Budecort respules are indicated in
a)
Maintenance and prophylactic treatment of asthma
b)
in infants and children with acute laryngotracheobronchitis (croup)
c)
Majorly B & Sometime B as depend on regular use of SABA
d)
none of the above
7.
What is the recommended dose for Budecort in Children (3 months to 12 years)?
a)
0.5 mg twice daily
b)
3-5 mg twice daily
c)
0.5-1.0 mg twice daily
d)
1-2 mg twice daily
8.
Initial pharmacological treatment for GOLD - group E
a)
Theophyline
b)
ICS/LABA
c)
LABA/LAMA
Consider LABA+LAMA+ICS* if blood eos ≥ 300]
d)
Systemic corticosteroids
9.
_____ Therapy should be considered as first choice for patients who get discharged after AECOPD
a)
Montherapy
b)
Dual Therapy
c)
Triple therapy
d)
All of the above
10.
Budesonide, beclomethasone, fluticasone are:
a)
Anti-inflammatory drugs
b)
Bronchodilators
c)
anticholinergic, inhaled corticosteroid
d)
Anti-inflammatory drugs & Bronchodilators
11.
GOLD - Group E
a)
mMRC ≥2 CAT ≥10; ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization
b)
mMRC 2-4; CAT >20; 2 moderate exacerbations (not leading to hospitalization)
c)
mMRC 0-2; CAT <20; 0 or 1 moderate exacerbations (not leading to hospitalization)
d)
mMRC ≥2 CAT ≥10; 0 or 1 moderate exacerbations (not leading to hospitalization)
12.
Foracort respules are indicated in the acute bronchospasm
a)
True
b)
False
13.
What is the dose of Foracort respules in asthma
a)
1 respule once daily
b)
1 respule twice daily
c)
2 respules twice daily
d)
1 respule thrice daily
14.
Prior to dispensing Foracort respules should be stored in
a)
10 - 15 deg. Celcius
b)
2 - 8 deg. Celcius
c)
15 - 20 deg. Celcius
d)
room temperature
15.
Clinical situations where Nebulizer is preferred over inhalers are
a)
Patient is incapable using MDI inhaler
b)
Inspiratory flow < 30L/min or Breath holding capacity < 4 secs
c)
Patient with recurrent episodes of acute airflow obstructions with pMDI
d)
All of the above
16.
Home maintenance nebulization involves delivering long-term maintenance drugs for___
a)
2 weeks
b)
≥3 months
c)
4 weeks
d)
≥3 weeks
17.
Glycopyrronium has ___times higher selectivity to ___receptors than tiotropium
a)
2, M4
b)
3.2, M9
c)
*10.7, M3
d)
10.7, M2
18.
In GOLDEN trial 3 & 4 - Improvement in lung function by nebulized Glycopyrrolate was quantified by which parameters ?
a)
PIFR
b)
PEFR
c)
Trough FEV1 and FVC
19.
In GOLDEN trial 3 & 4 - nebulized glycopyrrolate showed improvement in which of the secondary end-points?
a)
SGRQ score
b)
Night time symptom
c)
Exacerbation rate
d)
All of the above
20.
Which of following trial was a dose finding study for nebulized glycopyrrolate in COPD patients?
a)
GOLDEN trial 7
b)
GOLDEN trial 2 & 6
c)
GOLDEN trial 3 & 4
d)
GOLDEN trial 5
21.
In GOLDEN trial 5, Tiotropium had better cardiac safety profile than nebulized glycopyrrolate
a)
True
b)
False
22.
How much percentage of SGRQ responders were there in 25 ug of nebulized glycopyrrolate group in GOLDEN 3 trial?
a)
30%
b)
80%
c)
10-40%
d)
50 percent
23.
Which of the following doses of nebulized glycopyrrolate were effective in reducing night-time symptoms and % of exacerbation rate in GOLDEN trail 3 & 4?
a)
Glycopyrrolate 25 ug group
b)
Glycopyrrolate 50 ug group
c)
Placebo group
d)
Options A & B
24.
Post AECOPD patients are characterized by_____
a)
Increased QOL
b)
Increased PIFR
c)
Improved lung function
d)
Suboptimal PIFR
25.
What is the advantage of adding a high dose of ipratropium?
a)
Increases the duration of action
b)
Offers better symptom control & improvement in lung function
c)
Fastens the onset of action
d)
None of the above
26.
In duolin, levosalbutamol is ________ & ipratropium is __________
a)
beta 2 agonist, anticholinergic
b)
anticholinergic, beta 2 agonist
c)
anticholinergic, inhaled corticosteroid
d)
inhaled corticosteroid, beta 2 agonist
27.
Which of the following is true?
a)
Duolin LD respules strength is 1.25 mg Levasalbutamol and 500 mcg Ipratropium Bromide
b)
Duolin LD respules strength is .63 mg Levasalbutamol and 500 mcg Ipratropium Bromide
c)
Duolin LD respules strength is .63 mg Levasalbutamol and 250 mcg Ipratropium Bromide
d)
Duolin LD respules strength is 2.5 mg Levasalbutamol and 250 mcg Ipratropium Bromide
28.
Which of these is a distressing symtom
a)
*Sputum Retention
b)
Mucus expulsion
c)
Wheezing
d)
Cough
29.
What is the indication of Hyperneb
a)
For Mucus Retention
b)
For Mucus Expulsion
c)
*For Mucus Clearence
d)
For Mucus Adherence
30.
Which international body recommends Hypertonic Saline Inhalation for Bronchiectasis
a)
ECFS
b)
*ERS
c)
CFF
d)
IAP
Reset
